Erythropoietin: current status.
Understanding the regulation of red blood cell production has been greatly enhanced by the cloning and expression of the gene for human erythropoietin (Epo) and its receptor. The availability of recombinant human erythropoietin (rhEpo) for administration to patients has ushered in a new era in molecular medicine. Intravenous or subcutaneous administration of rhEpo can reliably cure the anemia of chronic renal failure and may be effective in the treatment of anemias secondary to chronic inflammation, malignancy, and marrow suppression from chemotherapy. In addition, rhEpo therapy will probably play a prominent role in transfusion medicine, both in preparing patients for auto-transfusions as well as in minimizing red cell transfusion requirements in the post-operative period.
Bunn
H F
HF
Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
D000740:Anemia / Q000188:drug therapy*; D003001:Cloning, Molecular; D004920:Erythropoiesis; D004921:Erythropoietin / Q000096:biosynthesis / Q000627:therapeutic use*; D006801:Humans; D011184:Postoperative Period; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin